ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2012 | $1,180,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jun 18, 2012 | $1,190,000 | Replaced |
| 1st Quarter - Amendment | Aug 16, 2012 | $1,110,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues related to US position on intellectual property matters in Canada Issues related to Non-tariff trade Barriers in Turkey
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| BRADLEY ALLEN ROSSIN | — |
Copyright/Patent/Trademark CPT
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY New | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Health Issues HCR
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY New | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Medicare/Medicaid MMM
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Consumer Issues/Safety/Products CSP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY New | — |
| ANDREW KAPLAN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Pharmacy PHA
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY New | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| KIRSTEN POWELL | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.